Cancer News and Research

Latest Cancer News and Research

Glycotope receives German, Italian regulatory approval for CetuGEX Phase I study for solid cancers

Glycotope GmbH, a leading glycobiology company, has received regulatory approval by German and Italian regulatory authorities for a Phase I study of Glycotope´s next generation antibody CetuGEX™ (GT-MAB 5.2-GEX) for the treatment of various solid cancers.

4 Aug 2010

Arcelis immunotherapy effective in treating autoimmune diseases: Study

Argos Therapeutics today announced that its Arcelis immunotherapy targeted at diabetes demonstrated potential for preventing and treating the disease in non-obese diabetic (NOD) mice, according to a peer-reviewed article published in Molecular Therapy.

4 Aug 2010

Celera decreases second-quarter net loss to $6.1 million

Celera Corporation today reported net revenues of $32.6 million for the second quarter of 2010 that ended June 26, 2010, compared to $41.4 million for the prior year quarter. For the second quarter of 2010, Celera reported a net loss of $6.1 million, or $0.07 per share, compared to a net loss of $31.7 million, or $0.39 per share, for the prior year quarter.

4 Aug 2010

QCMG selects SGI LiveArc storage solution for cancer genome sequence data processing

SGI, a global leader in HPC and data center solutions, today announced that the Queensland Centre for Medical Genomics at the University of Queensland has selected SGI LiveArc storage solution to increase its ability to store, manage and process human cancer genome sequence data. This project will contribute to mapping the genetic changes that lead to cancer, providing better understanding of such cancers and potentially helping to combat the disease.

4 Aug 2010

Cancer cells utilize fructose as an alternative to glucose for fueling growth: Study

A study published in the August issue of Cancer Research has resulted in several premature and potentially misleading conclusions when it comes to fructose and its effect on pancreatic tumor cells. Unfortunately, the media covering this story, and even the authors, have been too quick to extrapolate the results of laboratory research on pure fructose to real-world conditions, which is not appropriate or helpful to consumers.

4 Aug 2010

Children's hospitals, other medical centers now eligible for discounted drugs in Medicaid

The Hill: "Children's hospitals and other medical centers on Monday became eligible to enroll in a Medicaid program that offers discounted drugs, as called for in the healthcare reform law.

4 Aug 2010

$CTI files SPA with FDA for new pixantrone phase III trial in relapsed or refractory aggressive B-Cell NHL$

CTI files SPA with FDA for new pixantrone phase III trial in relapsed or refractory aggressive B-Cell NHL

Cell Therapeutics, Inc. today announced it has filed for a Special Protocol Assessment ("SPA") with the U.S. Food and Drug Administration ("FDA") for the design of its new phase III trial of pixantrone for patients with relapsed or refractory aggressive B-Cell non-Hodgkin's lymphoma ("NHL").

4 Aug 2010

Study solves puzzle behind different types of skin cancer on different body parts

A consistent all-over tan may be impossible to achieve because some body areas are much more resistant to tanning than others, a study has found.Researchers - funded by the Medical Research Council (MRC) - at the University of Edinburgh say the results explain why some holidaymakers find it so hard to achieve an even tan all over their body.

4 Aug 2010

Premier international conference to discuss latest diagnostic tools, emerging therapies for personalized medicine

What As scientists understand more about a tumor's underlying biology, personalized medicine is emerging as the new patient management paradigm. This year, the American Association for Cancer Research will host its fourth Molecular Diagnostics in Cancer Therapeutic Development: Challenges and Horizons conference at the Sheraton Denver Downtown Hotel in Denver, Colo. This meeting regularly draws representatives from academia and industry to discuss the latest in diagnostic tools and emerging therapies.

4 Aug 2010

Smokers are 11 times more likely to develop subareolar abscess

Women who smoke or pierce their nipples are more likely to develop a breast abscess, according to a new study in the July issue of the Journal of the American College of Surgeons. Researchers at the University of Iowa found the odds of developing primary breast abscess were six times higher in smokers than in nonsmokers, and smokers were 11 times more likely to develop subareolar abscess. Breast abscesses were 15 times more likely to recur in smokers than in nonsmokers. In addition, this study is one of the first to provide clinical evidence that nipple piercing is also a risk factor for subareolar breast abscess, with the onset of abscess occurring from one month to seven years from the time of piercing.

4 Aug 2010

ZymoGenetics second-quarter net loss declines to $3.8 million

ZymoGenetics, Inc. today reported substantially improved financial results for the quarter ended June 30, 2010. For the second quarter of 2010, the company's net loss declined to $3.8 million, or $0.04 per share, a $23.2 million improvement from the $27.0 million loss, or $0.39 per share, reported for the second quarter of 2009. The improvement resulted from higher revenues as well as reduced operating expenses.

4 Aug 2010

BCM collaborates with Roche NimbleGen for high throughput exome capture technology

The Baylor College of Medicine Human Genome Sequencing Center has standardized its target enrichment human disease research studies on Roche NimbleGen Sequence Capture Exome technology. The Baylor HGSC will sequence over 5,000 exomes in the next two years to identify genetic variants underlying multiple human diseases and will employ NimbleGen SeqCap EZ Exome and customized NimbleGen exome designs as the exome capture technology of choice. More than 15 different diseases will be investigated by Baylor HGSC, including brain, liver, pancreatic, colon, ovarian and bladder cancers, heart disease, diabetes, autism, and other inherited diseases with the goal of better understanding causative mutations and their impact on these diseases.

4 Aug 2010

Dendreon second-quarter revenue increases to $2.8 million

Dendreon Corporation today reported results for the quarter ended June 30, 2010. Revenue for the quarter ended June 30, 2010 was $2.8 million compared to $25,000 for the quarter ended June 30, 2009. Revenue for the six months ended June 30, 2010 was $2.8 million compared to $55,000 for the six months ended June 30, 2009.

4 Aug 2010

Study to understand processes that lead to onset of testicular germ cell cancer

Scientists have developed a model that will enable them to investigate, for the first time, how human testes develop in baby boys while they are in the womb. Until now it has been impossible to study testicular development during pregnancy in humans and this discovery will enable researchers to understand the processes that can lead to the onset of testicular germ cell cancer (TGCC) in young adult life, and how factors, such as common environmental chemicals, might play a role.

4 Aug 2010

Enzon second-quarter loss from continuing operations reduces to $5.4 million

Enzon Pharmaceuticals, Inc. today announced its financial results for the second quarter of 2010. For the second quarter of 2010, Enzon reported a loss from continuing operations of $5.4 million or $0.09 per diluted share, as compared to a loss of $19.7 million or $0.43 per diluted share for the second quarter of 2009.

4 Aug 2010

Kohl's, American Cancer Society announce new program to fight against breast cancer

As part of Kohl's Department Stores' commitment to fight breast cancer in Wisconsin with nearly $5 million to the American Cancer Society, Kohl's and the American Cancer Society announce new programs and resources available for Wisconsin women to help in their fight against breast cancer. New resources provide services for women fighting breast cancer and for those looking to learn more about preventative breast health.

4 Aug 2010

Long term decline in hemoglobin may announce onset of colorectal cancer

Anemia, a common blood disorder characterized by low hemoglobin levels, has long been associated with those suffering from colorectal cancer. But researchers at Tel Aviv University have discovered that, more than a symptom of active disease, low hemoglobin levels can actually indicate a potential for colon cancer years before it's diagnosed.

4 Aug 2010

Accuray receives Shonin approval to market CyberKnife G4 Robotic Radiosurgery System

Accuray Incorporated, a global leader in the field of radiosurgery, announced today it received Shonin approval from the Japanese Ministry of Health, Labor and Welfare to market the CyberKnife G4 Robotic Radiosurgery System to treat tumors non-invasively anywhere in the body, inclusive of head and neck. The System will be marketed in Japan as the "CyberKnife Radiosurgery System."

3 Aug 2010

Curis reports net loss of $2.1 million for second-quarter 2010

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the second quarter ended June 30, 2010.

3 Aug 2010

Celsion reports net loss of $2.6M for second-quarter 2010

Celsion Corporation, a biotechnology drug development company, today announced financial results for the second quarter and six months ended June 30, 2010 and addressed the progression of the clinical trials of ThermoDox, Celsion's heat activated liposomal encapsulation of doxorubicin. ThermoDox is currently being evaluated in the Phase III HEAT trial for the treatment of hepatocellular carcinoma and in a Phase I/II trial for patients with recurrent chest wall breast cancer.

3 Aug 2010

Cancer News and Research

Latest Cancer News and Research

Glycotope receives German, Italian regulatory approval for CetuGEX Phase I study for solid cancers

Arcelis immunotherapy effective in treating autoimmune diseases: Study

Celera decreases second-quarter net loss to $6.1 million

QCMG selects SGI LiveArc storage solution for cancer genome sequence data processing

Cancer cells utilize fructose as an alternative to glucose for fueling growth: Study

Children's hospitals, other medical centers now eligible for discounted drugs in Medicaid

CTI files SPA with FDA for new pixantrone phase III trial in relapsed or refractory aggressive B-Cell NHL

Study solves puzzle behind different types of skin cancer on different body parts

Premier international conference to discuss latest diagnostic tools, emerging therapies for personalized medicine

Smokers are 11 times more likely to develop subareolar abscess

ZymoGenetics second-quarter net loss declines to $3.8 million

BCM collaborates with Roche NimbleGen for high throughput exome capture technology

Dendreon second-quarter revenue increases to $2.8 million

Study to understand processes that lead to onset of testicular germ cell cancer

Enzon second-quarter loss from continuing operations reduces to $5.4 million

Kohl's, American Cancer Society announce new program to fight against breast cancer

Long term decline in hemoglobin may announce onset of colorectal cancer

Accuray receives Shonin approval to market CyberKnife G4 Robotic Radiosurgery System

Curis reports net loss of $2.1 million for second-quarter 2010

Celsion reports net loss of $2.6M for second-quarter 2010

Cancer Research - Second Edition eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in